{"groups":[{"description":"Participants were administered azacitidine 75 milligram per square meter (mg/m\\^2) intravenous (IV) or subcutaneous (SC) injection on Days 1 to 5, Days 8 and 9, in 28-day treatment cycles until disease progression or unacceptable toxicity or up to a maximum of 63 cycles.","id":"FG000","title":"Azacitidine 75 mg/m^2"},{"description":"Participants were administered azacitidine 75 mg/m\\^2 IV or SC injection on Days 1 to 5, Days 8 and 9 and pevonedistat 20 mg/m\\^2 IV infusion, on Days 1, 3, and 5 in 28-day treatment cycles until disease progression or unacceptable toxicity or up to a maximum of 63 cycles.","id":"FG001","title":"Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"27"},{"groupId":"FG001","numSubjects":"17"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"3"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"8"}],"type":"Reason Not Specified"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"227"},{"groupId":"FG001","numSubjects":"227"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"220"},{"groupId":"FG001","numSubjects":"223"}],"comment":"Safety Population included all enrolled participants who received at least 1 dose of azacitidine alone or pevonedistat + azacitidine.","type":"Safety Population"},{"achievements":[{"groupId":"FG000","numSubjects":"195"},{"groupId":"FG001","numSubjects":"199"}],"comment":"Participants were considered to have completed the study if they were followed until death or until the sponsor terminated the study.","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"32"},{"groupId":"FG001","numSubjects":"28"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Participants diagnosed with myelomonocytic, and myelogenous leukemia were randomized into two groups in 1:1 ratio to receive single-agent azacitidine or azacitidine + pevonedistat.","recruitmentDetails":"Participants took part in the study at 130 investigative sites globally from 28 November 2017 to 14 October 2024."}